Table 3.
Estimated number of participants per UCD phase per country.
| NL | GE | CZ | IT | IE | Total | |
|---|---|---|---|---|---|---|
| PHASE 1: EXPLORATION | ||||||
| Interviews | ||||||
| HDGECs | 36 | |||||
| preHD | 6 | 3 | 3 | 3 | 3 | |
| mHD | 6 | 3 | 3 | 3 | 3 | |
| Partners | 36 | |||||
| preHD | 6 | 3 | 3 | 3 | 3 | |
| mHD | 6 | 3 | 3 | 3 | 3 | |
| Focus groups | ||||||
| HCPs | 12 | 6 | 6 | 6 | 6 | 36 |
| Total phase 1 | 36 | 18 | 18 | 18 | 18 | 108 |
| PHASE 2: CONCEPT DEVELOPMENT | ||||||
| Co-creation sessions | * | – | – | – | – | * |
| Concept testing | * | – | – | – | – | * |
| Total phase 2 | * | – | – | – | – | * |
| PHASE 3: PROTOTYPE TESTING | ||||||
| Prototype testing | * | – | – | – | – | * |
| “Think-aloud” sessions | ||||||
| HDGECs | 40 | |||||
| preHD | 4 | 4 | 4 | 4 | 4 | |
| mHD | 4 | 4 | 4 | 4 | 4 | |
| Partners | 40 | |||||
| preHD | 4 | 4 | 4 | 4 | 4 | |
| mHD | 4 | 4 | 4 | 4 | 4 | |
| HCPs | 8 | 8 | 8 | 8 | 8 | 40 |
| Total phase 3 | 60 | 24 | 24 | 24 | 24 | 156 |
| Study total | 60 | 42 | 42 | 42 | 42 | 228 |
UCD, User-centered design; NL, the Netherlands; CZ, Czech Republic; GE, Germany; IT, Italy; IE, Ireland; HDGECs, Huntington's Disease gene expansion carriers; preHD, premanifest HDGECs; mHD, manifest HDGECs; HCPs, health care providers.
*
In the Netherlands, the same individuals that participated in the exploration phase (phase 1) will be asked to participate during co-creation and concept testing (phase 2), and prototype testing (phase 3). The bold values were meant to highlight the total sample size (as the bold values are the sum of the sample sizes of each individual study group).